palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B)	6- and 12-month survival probabilities	12633	12980	In all, 6- and 12-month survival probabilities were 57% (95% CI: 42–72%) and 27% (95% CI: 14–40%) for patients receiving 16 Gy/2 fr, and 30% (95% CI: 18–42%) and 11% (95% CI: 3–20%) for patients receiving 20 Gy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B)	Overall survival time	12454	12632	Overall survival time differed significantly between the study groups in favour of 16 Gy/2 fr (median 8.0 months), compared to 20 Gy/5 fr (median 5.3 months), P=0.016 (Figure 7).
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B)	degree of relief of all analysed symptoms	10526	11212	The percentages of all evaluable patients reporting any symptomatic improvement were as follows: cough 51% (24 out of 47; for a median of six assessments, range: 1–10), dyspnoea 60% (26 out of 43; for a median of six assessments, range: 1–9), haemoptysis 86% (19 out of 22; for a median of eight assessments, range: 1–11), chest pain 83% (34 out of 41; for a median of four assessments, range: 1–9), dysphagia 71% (five out of seven; for a median of eight assessments, range: 1–9), SVCS 83% (five out of six; for a median of five assessments, range: 4–9). The numbers of patients achieving symptomatic improvement did not differ between study groups for all analysed symptoms (Table 3).
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B)	degree of relief of all analysed symptoms	1125	1234	No significant differences between study arms were observed in the degree of relief of all analysed symptoms.
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B)	6- and 12-month survival probabilities	-1	-1	Overall survival time differed significantly between the study groups in favour of 16�??Gy/2 fr (median 8.0 months), compared to 20�??Gy/5 fr (median 5.3 months), P=0.016 (Figure 7). In all, 6- and 12-month survival probabilities were 57% (95% CI: 42�??72%) and 27% (95% CI: 14�??40%) for patients receiving 16�??Gy/2 fr, and 30% (95% CI: 18�??42%) and 11% (95% CI: 3�??20%) for patients receiving 20�??Gy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007)
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B)	degree of relief of all analysed symptoms	10526	11212	The percentages of all evaluable patients reporting any symptomatic improvement were as follows: cough 51% (24 out of 47; for a median of six assessments, range: 1–10), dyspnoea 60% (26 out of 43; for a median of six assessments, range: 1–9), haemoptysis 86% (19 out of 22; for a median of eight assessments, range: 1–11), chest pain 83% (34 out of 41; for a median of four assessments, range: 1–9), dysphagia 71% (five out of seven; for a median of eight assessments, range: 1–9), SVCS 83% (five out of six; for a median of five assessments, range: 4–9). The numbers of patients achieving symptomatic improvement did not differ between study groups for all analysed symptoms (Table 3).
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B)	Overall survival time	1235	1335	Overall survival time differed significantly in favour of arm B (median 8.0 vs 5.3 months; P=0.016).
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B)	Overall survival time	12454	12632	Overall survival time differed significantly between the study groups in favour of 16 Gy/2 fr (median 8.0 months), compared to 20 Gy/5 fr (median 5.3 months), P=0.016 (Figure 7).
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B)	6- and 12-month survival probabilities	-1	-1	In all, 6- and 12-month survival probabilities were 57% (95% CI: 42–72%) and 27% (95% CI: 14–40%) for patients receiving 16?Gy/2 fr, and 30% (95% CI: 18–42%) and 11% (95% CI: 3–20%) for patients receiving 20?Gy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B)	6- and 12-month survival probabilities	12633	12980	In all, 6- and 12-month survival probabilities were 57% (95% CI: 42–72%) and 27% (95% CI: 14–40%) for patients receiving 16 Gy/2 fr, and 30% (95% CI: 18–42%) and 11% (95% CI: 3–20%) for patients receiving 20 Gy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A)	palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B)	degree of relief of all analysed symptoms	1125	1234	No significant differences between study arms were observed in the degree of relief of all analysed symptoms.
